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Abstract
Smoking is the most important risk factor for the development of
chronic obstructive pulmonary disease (COPD). PatientswithCOPD
commonly suffer from skeletal muscle dysfunction, and it has
been suggested that cigarette smoke exposure contributes to the
development of skeletal muscle dysfunction even before overt
pulmonary pathology. This review summarizes the evidence that
muscles of nonsymptomatic smokers are weaker and less fatigue
resistant than those of nonsmokers. Although physical inactivity of
many smokers contributes to some alterations observed in skeletal
muscle, exposure to cigarette smoke per se can also induce skeletal
muscle dysfunction. Cigarette smoke constituents and systemic
inflammatory mediators enhance proteolysis and inhibit protein
synthesis, leading to loss of muscle mass. Reduced skeletal muscle
contractile endurance in smokers may result from impaired oxygen
delivery to the mitochondria and ability of the mitochondria
to generate ATP due to interaction of carbon monoxide with
hemoglobin, myoglobin, and components of the respiratory
chain. Besides hampering contractile function, smoking may have
immediate beneficial effects onmotor skills, which are attributable to
nicotine. In contrast to pulmonary pathology, many of the effects of
smoking on skeletal muscle are most likely reversible by smoking
cessation.
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Smoking is one of the most important risk
factors for the development of chronic
obstructive pulmonary disease (COPD).
Although patients with COPD commonly
suffer from exercise intolerance, such
a reduction in exercise capacity may
already be evident in smokers without
COPD. In fact, reductions in exercise
capacity even occur after just one session
of smoking (1), and nonsymptomatic
smokers more often complain of fatigue
than nonsmokers (2). Part of the
reductions in exercise capacity in
smokers may be related to changes in
skeletal muscle that precede the onset
of symptoms of COPD (3). Recently, the
attention for the impact of cigarette
smoke per se on skeletal muscle
function has evolved from providing
clinical evidence to unraveling the
pathophysiological mechanisms. This
review summarizes the evidence that
skeletal muscle dysfunction already exists
in smokers and cigarette smoke–exposed
animals without overt respiratory
problems. We focus on the impact
of cigarette smoking on two main
features of skeletal muscle function:
force-generating capacity and fatigue
resistance. Both sections are completed
by a perspective on the underlying
molecular mechanisms, based on findings
in humans, animal models, and in vitro
studies. Because physical inactivity,
observed in many smokers (4), may
contribute to muscular alterations (5),
we specifically indicate when studies
controlled for levels of physical activity
throughout the review. Finally, we
address the evidence that changes in
skeletal muscle are reversible by smoking
cessation.
Muscle Force-Generating
Capacity and Muscle
Mass in Smokers
In Vivo Evidence
Table 1 gives an overview of the studies on
the impact of smoking on muscle mass and
function. Several studies reported a lower
maximal force-generating capacity of
the quadriceps muscle of smokers than
nonsmokers (6, 7), but this is equivocal
(8). A study that matched smokers and
nonsmokers for levels of physical activity
did not observe a lower muscle force in
smokers (9), suggesting that disuse may
play a role in the loss of muscle strength
in smokers. A small effect of smoking per
se on muscle force cannot be excluded,
however, and large study populations may
be required to address this issue. A recent
longitudinal study in a large cohort of
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young healthy subjects showed that smoking
100 g tobacco per week was associated with
a 2.9 and 5% reduction of muscle force in
15 years, independent of physical activity,
in men and women, respectively (10).
Part of the muscle weakness may be
attributable to loss of muscle mass. Several
studies in humans and animal models
provide evidence that smoking does indeed
result in muscle wasting. For example,
a 25% smaller fiber cross-sectional area
was observed in the vastus lateralis muscle
of smokers (11), even when matched for
physical activity (12). In addition, lean body
mass is lower in smoking men compared
with similarly physically active nonsmoking
control subjects (8). This, however, could
also be the result of a lower food intake
secondary to smoking, which has hitherto
not been evaluated. Whatever the cause,
smoking has also been identified as
a risk factor for a low lean body mass in
community-dwelling elderly men even
without differences in physical activity (13).
Also, in rodents cigarette smoke exposure
results in fiber atrophy (14), reduced
muscle mass (15, 16), and progressive
myosin breakdown (17). Yet, the lower lean
body mass in human smokers was not
accompanied by lower maximal voluntary
muscle force (8). This intriguing finding
could be explained by the enhanced ability of
smokers to voluntarily activate their muscles
(9). Such improved ability to activate the
muscle may be the result of increased
sympathetic nerve activity caused by nicotine
(18). Thus, a fair amount evidence exists that
smoking per se can induce skeletal muscle
wasting, but with only modest effects on
maximal force-generating capacity.
Mechanisms of Smoking-induced
Muscle Wasting
Muscle wasting is the net result of an
increased protein degradation and/or reduced
protein synthesis. In smokers, the quadriceps
muscle displayed an increased expression
of muscle atrophy F-box (MAFBx) (19),
a muscle-specific regulating factor of
ubiquitin-mediated proteolysis. Similarly,
8 weeks of cigarette smoke exposure in
mice led in their limb muscles to increased
mRNA levels of MAFBx and Muscle Ring
Finger-1 (MuRF1), another regulator
of muscle proteolysis (16, 19). In vitro
studies on smoke-exposed muscle cells (i.e.,
myotubes) show atrophy and loss of myosin
concomitant with an increased expression
of MAFBx, MuRF1, and ubiquitin-specific
proteases (17, 20). Phosphorylation of p38
mitogen-activated protein kinase (MAPK)
and extracellular signal–regulated kinase
(ERK) appears to play a central role, as
inhibition of p38 and ERK abolishes muscle
atrophy, myosin degradation, and the
activation of the ubiquitin–proteasome
pathway in smoke-exposed myotubes
(17, 20). The smoke-induced increase in
MuRF1expression in myotubes can also
Table 1. The Impact of Smoking on Skeletal Muscle Mass and Function
Species Mass Force Fatigue Resistance Comments on Design Comments on Results Reference
Mouse Gastrocnemius &
soleus ↓
Smoking 8 & 24 wk 60 d cessation: soleus
restored, gastrocnemius
still lower mass
15
Mouse Calf muscle
complex ↓
Soleus: Smoking 8–16 wk 16
8 wk =
16 wk ↓
EDL =
Rat EDL, type IIA and IIB
fiber atrophy
Smoking 8 wk Effects only in high dose 14
Rat Quadriceps, myosin
loss
Smoking 4–12 wk Lung lesions detectable
after 12 wk
17
Human VL, type I atrophy 11
Human VL = = ↓ Electrically evoked
contractions
No correlation with
physical activity
(questionnaire)
9
Human VL, fiber atrophy
ACSA =
= ↓ Electrically evoked
contractions
No correlation with
physical activity
(questionnaire)
12
Human VL, fiber atrophy = Repeated voluntary
dynamic contractions
Monozygotic twin. Similar
physical activity level.
No differences in
monozygotic
nonsmoker–ex-smoker
pairs
28
Human VL = ↓ = Repeated voluntary
dynamic contractions
Similar physical activity
level
29
Human Quadriceps = ↓ 7
Human = ↓ 6
Human Lean mass ↓ = Independent of physical
functioning
8
Human Lean mass ↓ ↓ Independent of physical
activity
10
Definition of abbreviations: ACSA = anatomical cross-sectional area; EDL = extensor digitorum longus; VL = vastus lateralis muscle.
Equal signs indicate no change.
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be abolished by inhibition of nuclear
factor-kB (NF-kB) (20). The following
pattern thus emerges that substances
in smoke stimulate p38 and ERK1/2
phosphorylation, which in turn enhances
the expression of MuRF1 via NF-kB
activation, and MAFBx independent of
NF-kB activation (Figure 1). However, in
mice exposed to cigarette smoke for 8 weeks,
gastrocnemius muscle mass decreased
without enhanced MuRF1-protein levels
(15), indicating that also other pathways
might be involved in smoke-induced
muscle wasting. Indeed, besides stimulating
protein degradation, smoke exposure may
also inhibit anabolic pathways. Muscle
protein synthesis, as assessed by the
incorporation of labeled leucine, is decreased
in the quadriceps muscle of smokers (19),
which was associated with an increased
expression of myostatin (19). Myostatin
inhibits muscle growth by inactivation of
protein kinase B (also known as Akt),
a promoter of protein synthesis, and
by hampering muscle cell renewal (21).
In accordance, cigarette smoke exposure
respectively reduces the presence of active
Akt in mice skeletal muscle (15) and impairs
the differentiation of cultured muscle cells
into myotubes (17). It thus appears that
smoking both stimulates protein breakdown
and inhibits protein synthesis.
Cigarette smoke contains thousands of
substances, and several of those potentially
stimulatemuscle protein breakdown and impair
protein synthesis, as extensively reviewed in
Reference 22. Among these constituents,
aldehydes are capable of entering the
circulation and directly affecting skeletal muscle
tissue. Acetaldehyde exposure, for example,
reduces protein synthesis rate in cultured
human muscle cells (23). Another aldehyde,
acrolein, induces atrophy and myosin
breakdown in murine myotubes in a dose- and
duration-dependent manner via p38 MAPK
phosphorylation (24).
Circulating proinflammatory cytokines
may also contribute to smoking-induced
muscle wasting. Exposure of animals to
cigarette smoke increases blood levels
of proinflammatory cytokines, especially
tumor necrosis factor (TNF)-a (16). In the
circulation of smoking humans, IL-6 rather
than TNF-a levels are higher than in
nonsmokers (8, 19). Both TNF-a and IL-6
can induce skeletal muscle wasting by
enhancing proteolysis and inhibiting
protein synthesis (25). The exact origin of
these circulating cytokines is unclear, but
might include spill-over from the lung,
activated leukocytes, and organ systems like
bone marrow and skeletal muscle itself (26).
Although in skeletal muscles of smoke-
exposed guinea pigs and smoking humans
no evidence of enhanced expression of
cytokines has been found (6), the induction
of TNF-a in skeletal muscle may be
duration dependent. This is supported by
the elevated expression of TNF-a in skeletal
muscle from mice after 24 but not 8 weeks
of cigarette smoke exposure (15). That
muscle wasting in smoking mice depends
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Figure 1. Mechanisms whereby smoking may affect skeletal muscle mass and function. ERK = extracellular signal–regulated kinase; MAFBx =muscle
atrophy F-box; MAPK =mitogen-activated protein kinase; MuRF1 =muscle ring finger-1; NF-kB = nuclear factor-kB; ROS = reactive oxygen species;
TNF-a = tumor necrosis factor-a.
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on the action of TNF-a is supported by
the attenuation of both atrophy and the
IIa-IIb fiber type shift in smoking TNF-a
receptor-2 knockout mice (27).
In summary, circulating constituents
of cigarette smoke and cytokines can
cause smoking-induced muscle wasting
through activation of muscle proteolysis
and inhibition of protein synthesis.
Skeletal Muscle Fatigue
Resistance in Smokers
In Vivo Evidence
Muscle fatigue resistance, or endurance, is
defined here as the ability of the muscle to
maintain a given force or power output.
Studies from Larsson and Orlander (28) and
Orlander and colleagues (29) showed that
neither isometric nor dynamic endurance
was impaired in smokers compared with
nonsmokers. More recently, however, Wu¨st
and colleagues found a reduced fatigue
resistance in the quadriceps muscle of
smokers (12). The main difference between
these studies is that the former used
voluntary contractions, whereas the latter
applied electrically evoked contractions
to study muscle fatigability. Electrically
evoked contractions have the advantage
that motivational bias is circumvented,
a factor that is particularly important during
prolonged duration of contractile activity
(30). In the context of smoking this is even
more relevant, because muscle activation
was z4% higher during voluntary
contractions in smokers than nonsmokers
(9), which may result in delayed onset of
fatigue during prolonged contractile activity
in smokers. The enhanced ability of smokers
to activate their muscles may be caused by
nicotine. In fact, nicotine has been shown to
improve exercise endurance, probably via
a central mechanism (18). It is thus possible
that an increased central drive during
sustained or repeated voluntary contractions
effectively overcomes any reduction in
muscle fatigue resistance in smokers,
whereas the electrically evoked fatigue
reflects detrimental effects on intrinsic
muscle contractility.
Mechanisms of Smoking-induced
Reduced Fatigue Resistance
Fiber type composition. In general, muscle
fatigue resistance is related to the oxidative
capacity of the muscle (31). Accordingly,
a fiber type transition from oxidative type I
fibers to more glycolytic type II fibers may
underlie the reduced fatigue resistance
of smokers. Indeed, one of the earliest
investigations reported that smokers had
a lower proportion of type I fibers in the
vastus lateralis muscle than nonsmokers
(29). To exclude the impact of differences in
genotype between individuals, Larsson and
O¨rlander studied monozygotic discordant
twins and found that the smoking twin had
smaller and a lower proportion of type I
fibers than the nonsmoking twin (28).
Although this suggests that smoking itself
causes these changes, the physical activity
of the smoking twins tended to be lower.
As disuse induces a slow-to-fast fiber type
transition (5), it is possible that such changes
in muscles from smokers are the result of
disuse (28) rather than smoking itself. The
potential importance of disuse is also
reflected by two studies reporting a similar
fiber type composition of the vastus lateralis
muscle in activity-matched smokers and
nonsmokers (11, 12). Despite the absence
of a fiber type transition, the study from
Montes de Oca and colleagues (11) still
showed a reduced skeletal muscle oxidative
capacity in smokers. Wu¨st and colleagues
(12) did not observe significantly lower
succinate dehydrogenase activity in skeletal
muscles from smokers, but this could be
explained by a lower smoke exposure in
their subjects: average of 30 pack-years (.20
yr) (11) versus 12.9 pack-years (2.9–35) (12),
respectively. Nevertheless, future studies
should obtain a better indication of the
physical activity level of their smoking
participants or the smoking rodents.
Skeletal muscle oxygen delivery.
Because the reduced muscle fatigue
resistance observed in smokers (9, 32) is
hardly explicable by changes in fiber type
composition or oxidative enzyme activity
(12), another factor must cause the reduced
muscle fatigue resistance in smokers. Such
a situation could occur when the oxygen
delivery to the mitochondria, or the ability
of the mitochondria to use the oxygen, is
impaired (Figure 1).
The arterial vascular resistance increases
(33) and the vasodilatory response in smokers
worsens with duration of smoking (34).
Consequently, the blood flow and hence
oxygen delivery to the active muscle may be
diminished and contribute to some of the
increased muscle fatigability in smokers. As
NO plays an important role in vasodilation,
the reduced expression of neuronal and
endothelial nitric oxide synthase in smokers
(11) may underlie the reduced vasodilatory
response. Despite the reduced vasodilatory
response, muscle capillarization is not
significantly affected by smoking (11, 12, 28).
Probably the most important factor in
cigarette smoke that hinders the delivery of
oxygen to the working muscle is CO. The
affinity of hemoglobin for CO is 200-fold
stronger than for oxygen. The association
of CO with hemoglobin results in
carboxyhemoglobin (COHb), which
effectively reduces the oxygen carrying
capacity of the blood. Smokers may have
up to 9% COHb (35), which could thus be
compared with a hypoxemic condition.
Yet, reducing the SaO2 to 80% by inhaling
hypoxic air (inspiratory oxygen 12%) did
not significantly reduce muscle fatigue
resistance during repeated electrically
evoked contractions (36). However, in
addition to a reduction in the oxygen
carrying capacity, the CO-induced left shift
of the oxyhemoglobin dissociation curve
impairs the delivery of oxygen to the
mitochondria in the active muscle. That this
is important is reflected by the increased
oxygen extraction in hypoxic (inspiratory
oxygen 9%) working dog muscles, whereas
it is reduced with COHb (37). Raising the
COHb to 6% in humans by inspiring CO
acutely reduced fatigue resistance (38). In
smokers, this is to some extent compensated
for by an increased hematocrit, which can
return to normal values within 3 days of
smoking cessation (39). It thus appears that
CO in cigarette smoke may diminish muscle
fatigue resistance via formation of COHb
that results in (1) a reduced oxygen carrying
capacity of the blood, and (2) an impaired
oxygen delivery consequent to the left shift
of the Hb-dissociation curve.
Although the myoglobin (Mb)
concentration of the muscle did not differ
between smokers and nonsmokers (12),
CO in cigarette smoke may combine
with Mb and thereby hamper facilitated
oxygen diffusion within the cell, even
in the presence of an unaltered [Mb]
(40). Ultimately, this may impair the
delivery of oxygen to, in particular, the
intermyofibrillar mitochondria.
Mitochondrial function. Although part
of the reduced muscle fatigue resistance in
smokers can be ascribed to impaired oxygen
delivery to the muscle, interference of
substances in cigarette smoke with the
mitochondrial respiratory chain may
hamper aerobic ATP production and hence
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result in increased muscle fatigability. For
instance, cyanide, CO, and lung-secreted
ceramides inhibit cytochrome-c oxidase
(complex IV) in isolated mitochondria from
skeletal muscle (41, 42), which may well
underlie the lower complex IV activity in
skeletal muscle mitochondria of active
smokers (28, 29). This process is potentially
rapid, as acute smoking (five cigarettes in
45 min) in healthy nonsmokers leads to an
immediate decrease in complex IV activity
in blood cells that normalized after as little
as 24 hours’ smoking cessation (43). The
ultimate significance of inhibition of these
complexes has not yet been determined,
but the final consequence is the loss of
the capacity for the mitochondria to
produce ATP (43). Obviously, this
may be particularly harmful in high-
energy–dependent tissues such as skeletal
muscles, the brain, and the heart.
Furthermore, dysfunctional
mitochondria are notorious producers of
reactive oxygen species (44). Accordingly,
mitochondrial dysfunction in lymphocytes
from smokers is accompanied by increased
membrane peroxidation (45). It seems
therefore plausible that smoke-induced
mitochondrial dysfunction in skeletal
muscle cells (28, 29, 42) may also lead
to increased reactive oxygen species
generation and result in oxidative
modifications of skeletal muscle proteins. In
addition, it should be noted that cigarette
smoke itself contains a host of free radicals
(22). In line with this hypothesis, several
skeletal muscle proteins involved in energy
metabolism and contraction display
oxidative modifications in the quadriceps
of smoking humans compared with
nonsmoking control subjects (6).
Furthermore, 3 months of cigarette smoke
exposure was sufficient to induce similar
modifications in skeletal and respiratory
muscles of guinea pigs (6). Oxidative stress
can impair contractile protein function (46)
and is therefore expected to contribute to
smoking-induced muscle dysfunction.
Effects of Smoking Cessation
Much of the decrement in skeletal muscle
fatigue resistance in smokers is related to
the acute effects of substances in smoke
on oxygen delivery and the ability of the
mitochondria to use oxygen. This is
supported by the observation that the
lower skeletal muscle fatigue resistance in
smokers was not related to pack-years or
cigarettes smoked per day (9) and that
similar reductions in fatigue resistance can
acutely be achieved by CO inhalation
(38). If so, some of the smoking-related
changes in skeletal muscle function should
be rapidly reversible by smoking cessation.
Studies in lymphocytes have reported
that smoking cessation for as little as
24 hours to 7 days resulted in restored
complex III and IV activities and oxygen
consumption (43, 47). It is likely that
such improvements with smoking
cessation will occur also in skeletal
muscle, but this has hitherto not been
explored. It is expected that the restoration
of normal function will take somewhat more
time than that observed for blood cells that
are more directly exposed to components
in cigarette smoke than muscle tissue. In
this context, it is encouraging to see that
nonsmoking patients with COPD have
a similar muscle fatigue resistance as
activity-matched healthy people (48).
Another factor that may contribute to
the improvement in fatigue resistance
would be normalization of vascular
resistance after smoking cessation as
observed in former smokers (34). Also,
the detrimental effects of smoking on
muscle wasting are likely reversible, as
a 60-day smoking cessation period was
sufficient to normalize the muscle cell
signaling alterations and reverse the loss
of soleus muscle mass induced by 24-
weeks’ cigarette smoke exposure in mice
(15). This was, however, not the case for
the gastrocnemius muscle, which might
indicate that not all muscles respond
similarly to smoking cessation. In
postmenopausal women, 16 months of
smoking cessation was associated with
an increase in muscle mass (49), and the
absence of atrophy in the ex-smoker
sibling of monozygotic twins (28) also
fits the notion that smoking cessation can
reverse smoking-induced muscle wasting.
In agreement, both skeletal muscle force-
generating capacity and the lean body mass of
formerly smoking subjects are not different
from never-smoking control subjects (8),
suggesting that the recovery of muscle mass
is also associated with a normalized muscle
function. This is further supported by the
observation that nonsmoking patients
with COPD do not show reduced muscle
strength compared with age- and physical
activity–matched healthy nonsmoking
control subjects (48). Thus, although
smoking-induced changes in the lung are
irreversible (50), skeletal muscle may well
recover from cigarette smoke–induced
wasting, weakness, and increased fatigability
by smoking cessation.
Conclusions
In summary, skeletal muscle weakness
and reduced fatigue resistance exist in
nonsymptomatic human smokers and
cigarette smoke–exposed animals without
overt pulmonary disorders. This indicates
that cigarette smoke itself contributes
to the development of skeletal muscle
dysfunction, even before pulmonary
problems are evident. Circulating cigarette
smoke constituents seem to play an
important role in the underlying molecular
mechanisms, as these induce muscle
wasting, reduce oxygen delivery, and
impair mitochondrial function. There is
some evidence that skeletal muscle may
recover from cigarette smoke–induced
impairments, but future studies should
establish whether smoking cessation indeed
restores muscle function. For example,
muscle function could be evaluated in
a cohort of subjects who participate in quit-
smoking programs. Promising results are
at least expected in terms of normalization
of vascular and mitochondrial function,
because these impairments occur rapidly.
If indeed smoking cessation has immediate
beneficial effects on mitochondrial,
vascular, and muscle function, this may
provide an important extra stimulus to stop
smoking and thereby avert the “explosion
of the smoking time bomb” in later life. n
Author disclosures are available with the text
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